![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Under the terms of agreement, Poly Pharm will manufacture clinical batches and, if approved, will also manufacture commercial batches for Celsion’s vaccine based on TheraPlas technology. TheraPlas underlies Celsion’s GEN-1 product and its PLACCINE vaccine technology platform.
Lead Product(s): DNA-based COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Placcine Covid 19 Vaccine
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Imunon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 17, 2021